.tb-field[data-toolset-blocks-field="e2d01709a3f8de58acaabc06a5d6ce4b"] { font-size: 12px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="7474eb380d2281f3effdd3d227b39ca8"] { font-size: 12px;padding: 0px;margin: 0px; }  .tb-field[data-toolset-blocks-field="9bf3ca162c40d45e3437cc852cc1b44b"] { font-size: 12px;padding: 0px;margin: 0px; }  .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom} .wp-block-image.tb-image[data-toolset-blocks-image="24f3c86f6bd5748b83fd13e65576476a"] { max-width: 100%; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .wpv-pagination-nav-links[data-toolset-views-view-pagination-block="f6980ece1395d45bbc903f8d235d7482"] { text-align: left;justify-content: flex-start; } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { background-color: rgba( 217, 217, 217, 0.13 );padding: 10px;margin-bottom: 15px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 );border: 1px solid rgba( 215, 213, 213, 1 );grid-template-columns: minmax(0, 0.665fr) minmax(0, 0.335fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }   .wpv-custom-search-filter-submit[data-toolset-views-custom-search-submit="8ca7a9b3f80df5aa18fe74ad2a58d731"] { text-align: left; } h1.tb-heading[data-toolset-blocks-heading="47d6f587a902cf3e8b61faa17147b218"]  { font-size: 26px; }  @media only screen and (max-width: 781px) {    .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } @media only screen and (max-width: 599px) {    .tb-image{position:relative;transition:transform 0.25s ease}.wp-block-image .tb-image.aligncenter{margin-left:auto;margin-right:auto}.tb-image img{max-width:100%;height:auto;width:auto;transition:transform 0.25s ease}.tb-image .tb-image-caption-fit-to-image{display:table}.tb-image .tb-image-caption-fit-to-image .tb-image-caption{display:table-caption;caption-side:bottom}.tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wpv-view-output[data-toolset-views-view-editor="09de6734590db99da81961511f8ed090"] .js-wpv-loop-wrapper > .tb-grid { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid,.tb-grid>.block-editor-inner-blocks>.block-editor-block-list__layout{display:grid;grid-row-gap:25px;grid-column-gap:25px}.tb-grid-item{background:#d38a03;padding:30px}.tb-grid-column{flex-wrap:wrap}.tb-grid-column>*{width:100%}.tb-grid-column.tb-grid-align-top{width:100%;display:flex;align-content:flex-start}.tb-grid-column.tb-grid-align-center{width:100%;display:flex;align-content:center}.tb-grid-column.tb-grid-align-bottom{width:100%;display:flex;align-content:flex-end} .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .wp-block-toolset-blocks-grid.tb-grid[data-toolset-blocks-grid="c3d01c7f0eaacb3eed155ab31795f301"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .wp-block-toolset-blocks-grid-column.tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; }     } 

Company Directory

PharmaTargeting

Category: BioManufacturing

https://www.pharmatargeting.com/

+44 (0) 20 3780 7100

40 Heath Street, Suite B, London, NW3 6TE, United Kingdom

Pharming Group NV

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical

https://www.pharming.com/

info@pharming.com

Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

PHASTAR

Category: Pharmaceutical Contractors

https://www.phastar.com

tellmemore@phastar.com

Unit 2, 2A Bollo Ln, Chiswick, London W4 5LE

PHC North America

Category: BioManufacturing

https://www.phchd.com/us/biomedical/about-us

info@us.phchd.com

1300 Michael Drive, Suite A, Wood Dale, IL 60191 Toll Free USA

Phenomenex

Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, clinical research, government and academic laboratories. The biopharmaceutical industry is specifically supported by novel separation technology designed and manufactured for the analysis of biologics. Incorporating a novel biocompatible titanium hardware, the...

Category: Pharmaceutical

https://www.phenomenex.com/

ukinfo@phenomenex.com

Queens Avenue, Hurdsfield Ind. Est., Macclesfield, Cheshire, SK10 2BN, UK

Phesi

Category: Clinical Trials

https://www.phesi.com/

info@phesi.com

East Lyme, Connecticut, US

Phillips-Medisize

Phillips-Medisize, a Molex company, is a complete provider of outsource strategy, design, development and manufacturing services to the global drug delivery, pharmaceutical, medical device and diagnostic markets. Phillips-Medisize offers complete end-to-end capabilities for Pharma customers from early device strategy through full scale production and integrated supply chain management. Customised drug delivery devices developed and/or produced...

Category: Manufacturing and Packing

https://www.phillipsmedisize.com

eu_sales@phillipsmedisize.com

Edisonstraat 1 Hillegom 2181 AB

PHOENIX group

The PHOENIX group is a leading pharmaceutical wholesaler and retailer in Europe, ensuring that prescription and over-the-counter medicines always get to the right place at the right time in 26 countries. PHOENIX group´s vision is to be the best integrated healthcare provider wherever we are. With PHOENIX All-in-One, PHOENIX provides services for pharmaceutical companies...

Category: Clinical Trials

https://www.phoenix-all-in-one.eu

s.schomburg@phoenixgroup.eu

Sandra Schomburg European Clinical Trial Supply Manager Pharma Services Europe Pfingstweidstraße 10-12 D-68199 Mannheim, Germany

Phoremost Ltd

Category: Pharmaceutical

https://www.phoremost.com

info@phoremost.com

PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom

Phynova

Category: BioManufacturing

https://www.phynova.com/

info@phynova.com

Phynova House, 16 Blenheim Office Park, Long Hanborough, Oxfordshire, OX29 8LN, United Kingdom

Pierre Fabre Laboratories

Category:

https://www.pierre-fabre.com/en

laurence.marchal@pierre-fabre.com

1 Avenue d'Albi, Castres, Occitanie 81100, Tarn, France.

Pill Connect

Category: Drug Delivery, Logistics, Pharmaceutical

https://www.pillconnect.com/

info@pill-connect.con

125 Deansgate, Manchester, M2 3BY, UK

PlaqueTec

Category: Clinical Trials

https://www.plaquetec.com/

info@plaquetec.com

Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT

PlasmidFactory GmbH & Co. KG

PlasmidFactory GmbH & Co. KG, based in Bielefeld, Germany, is the leading contract manufacturer of plasmid and minicircle DNA. The company offers the production of plasmids and minicircles in several Quality Grades: Research Grade and ccc Grade for research purposes and pre-clinical applications, High Quality (HQ) Grade as starting material for e.g. GMP production of...

Category: Manufacturing and Packing